Grit Biotechnology

This study tests a new treatment called GT307, which uses immune cells taken from a patient's own tumor to fight advanced colorectal cancer. The goal is to see if it is safe and can shrink tumors. About 18 adults whose cancer has worsened after first-line chemotherapy will take p…

This early-stage trial tests a new treatment called GT801 for people with moderate-to-severe autoimmune diseases that haven't improved with standard therapies. The study will enroll 22 participants to check safety and how well the treatment works. Researchers will monitor side ef…

This study tests a new treatment called GT201 for people with advanced solid tumors. GT201 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are grown in a lab and then given back to fight the cancer. The trial aims to find a safe dose and see if it can shri…

This early-stage study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. cGVHD is a complication after a stem cell transplant where donor cells attack the patient's body. The main goals a…

This early-stage study tests a new treatment called GT801 in 28 adults with certain blood cancers (like leukemia and lymphoma) or an autoimmune blood disorder (AIHA) that have not responded to standard therapies. The treatment uses specially modified cells to target a protein cal…

This early-phase study tests a new treatment called GT101 for people with advanced solid tumors that have spread or come back. GT101 uses immune cells taken from the patient's own tumor, multiplied in a lab, and then given back to the patient. The study aims to check if this appr…

This early-stage study tests an injection called GT719 in 10 adults with moderate to severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the treatment helps cont…

This early-stage trial tests an experimental therapy using a patient's own immune cells (TILs) to fight advanced solid tumors that have spread or come back. About 12 adults with certain cancers will receive the treatment after chemotherapy. The main goal is to check safety and si…

This early-stage study tests a new treatment called GT719 for people with severe neurological autoimmune diseases that have not responded to other therapies. The treatment uses specially designed cells to target the immune system's attack on the nerves. The study will check if th…

This early-phase study tests an experimental treatment called IB-T101 for adults with advanced clear cell kidney cancer. The therapy uses a patient's own immune cells (TILs) to fight the tumor. The main goals are to check safety and see if the treatment shrinks tumors. Only 12 pa…

This early-stage trial tests a personalized treatment called GT307, made from a patient's own tumor-fighting immune cells. It aims to see if the therapy is safe and can shrink tumors in 18 adults with advanced solid cancers, such as ovarian cancer. The study is currently recruiti…

This early-phase study tests an experimental cell therapy called GT719 for adults with relapsed or refractory B-cell blood cancers (lymphoma and leukemia) that have not responded to standard treatments. The therapy uses donor-derived immune cells designed to attack cancer cells c…

This early study tests a personalized treatment called GT307, made from a patient's own tumor-fighting immune cells. It is for adults with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the best dose, while also lo…

This study tests an experimental treatment called GT719 for adults with certain blood cancers (B-cell lymphoma or leukemia) that have not responded to standard therapy or have returned. The treatment is a type of cell therapy that targets a protein called CD19 on cancer cells. Th…

This early study tests a new treatment for people with advanced head and neck cancer that has come back or spread. The treatment uses a patient's own immune cells (called TILs) that are grown in a lab and given back along with a drug that helps them attack the cancer. The main go…

This study tests a new treatment called GT101, which uses immune cells taken from a patient's own tumor to fight their cancer. It is for people with cervical cancer that has come back or spread. The study compares GT101 to a standard chemotherapy drug to see which works better an…

This early-stage study tests an injection called GT719 in 30 people with moderate to severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose, while also seeing if it helps control the disease. Participants mu…